Putting the Microenvironment into the Immunotherapy Companion Diagnostic

Myrto Moutafi; David L Rimm

doi:10.1158/1078-0432.CCR-21-1238

Putting the Microenvironment into the Immunotherapy Companion Diagnostic

Clin Cancer Res. 2021 Jul 15;27(14):3812-3814. doi: 10.1158/1078-0432.CCR-21-1238. Epub 2021 May 13.

Authors

Myrto Moutafi¹, David L Rimm²

Affiliations

¹ Department of Pathology, Yale University School of Medicine, New Haven, Connecticut.
² Department of Pathology, Yale University School of Medicine, New Haven, Connecticut. david.rimm@yale.edu.

PMID: 33986024
DOI: 10.1158/1078-0432.CCR-21-1238

Abstract

A post hoc analysis in advanced gastric cancer showed stronger association of programmed cell death-ligand 1 (PD-L1) with immunotherapy efficacy measured by combined positive score (CPS) compared with tumor cells (TC%). This finding suggests expression in immune cells in the tumor microenvironment increases the value of the companion diagnostic test.See related article by Lei et al., p. 3926.

Publication types

Comment

MeSH terms

B7-H1 Antigen* / genetics
Humans
Immunotherapy
Lymphocytes, Tumor-Infiltrating
Stomach Neoplasms* / diagnosis
Stomach Neoplasms* / therapy
Tumor Microenvironment

Substances

B7-H1 Antigen